Adamis pharmaceuticals submits fast track application to fda for tempol for the treatment and prevention of covid-19

San diego, jan. 10, 2022 (globe newswire) -- adamis pharmaceuticals corporation (nasdaq: admp) today announced the submission of a fast track application to the u.s. food and drug administration (fda) for tempol for the treatment and prevention of covid-19. tempol is currently being studied in a phase 2/3 clinical trial in adult patients with confirmed covid-19 infection. tempol has been shown to have antiviral, anti-inflammatory, and antioxidant activity. although recent oral antiviral drugs have been approved by the fda, the company believes that tempol would provide an unmet medical need because of its unique mechanism of action and safety profile.
ADMP Ratings Summary
ADMP Quant Ranking